Detalles de la búsqueda
1.
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis
; 20: 14799731231202257, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37800633
2.
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
Respirology
; 27(12): 1034-1044, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35970518
3.
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Respir Res
; 22(1): 279, 2021 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34711232
4.
Measuring disease activity in COPD: is clinically important deterioration the answer?
Respir Res
; 21(1): 134, 2020 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487202
5.
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.
Respir Res
; 20(1): 60, 2019 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-30914064
6.
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Respir Res
; 20(1): 238, 2019 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31666084
7.
Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Pulm Pharmacol Ther
; 57: 101802, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31096036
8.
Long-term outcomes following first short-term clinically important deterioration in COPD.
Respir Res
; 19(1): 222, 2018 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30453972
9.
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Respir Res
; 22(1): 299, 2021 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34801035
10.
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Pulm Pharmacol Ther
; 29(1): 49-57, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25020273
11.
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT Study.
Pulm Ther
; 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38446336
12.
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
Br J Clin Pharmacol
; 75(6): 1478-87, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23116485
13.
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.
Respir Med
; 200: 106918, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35803172
14.
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Int J Chron Obstruct Pulmon Dis
; 16: 1925-1938, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34194225
15.
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
Int J Chron Obstruct Pulmon Dis
; 16: 1939-1956, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34234425
16.
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
Adv Ther
; 38(9): 4815-4835, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34347255
17.
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.
Int J Chron Obstruct Pulmon Dis
; 16: 1215-1226, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33976543
18.
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Int J Chron Obstruct Pulmon Dis
; 16: 3105-3118, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34916789
19.
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Ther Adv Respir Dis
; 14: 1753466620968500, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33167780
20.
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
Ther Adv Respir Dis
; 14: 1753466620926949, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32462979